Example collocations logo

Vaccine in sentence

824 examples of Vaccine in a sentence

Recent breakthroughs in basic science give hope that a vaccine can be developed within a decade, if the billions of dollars of research and development funds are mobilized by both public and private sectors.
We are less accustomed to thinking of global cooperation to promote new technologies, such as clean energy, a malaria vaccine, or drought-resistant crops to help poor African farmers.
The Bacille de Calmette et Guérin (BCG) vaccine – the only one available for the disease, and the main pillar of TB prevention – is only partly effective.
And, although several new vaccine candidates have passed preliminary clinical tests, BCG will remain the only available vaccine for years to come.
And the right care requires rapid development and dissemination of new tools, including quick point-of-care diagnostic tests, safe and fast-acting drugs, and an effective TB vaccine.
To be sure, good surveillance is needed in order to obtain early warning that a strain of H5N1 flu transmissible between humans has been detected, so that nations around the world can rapidly initiate a variety of public health measures, including a program to produce large amounts of vaccine against that strain.
But, if we’re ready to rush the pandemic strain into an emergency program to manufacture vaccine, we could possibly blunt the second wave.
The world needs a vaccine and a cure to get ahead of the disease, and great progress is being made in both areas.
Moreover, long-term treatment is not the same as a cure, and no public-health tool (apart from clean drinking water) has ever matched the preventive power of a vaccine.
Although there are no precedents that might guide us to a vaccine or cure, we have learned a lot about how HIV works – and its weaknesses – in the last five years.
In 2009, for example, researchers found so-called “proof of concept” when a clinical trial showed that a vaccine could prevent HIV infection in humans, and Timothy Ray Brown (known as “the Berlin patient”) was cured of HIV via a bone-marrow transplant.
With the insights gained from following these patients, researchers are increasingly beginning to recognize that the same science may bring us to both a vaccine and a cure.
For example, scientists working to design a vaccine that will induce production of broadly neutralizing antibodies to protect people from HIV infection have found that these antibodies also control and even clear infection by the simian version of the virus in monkeys.
A similar result, dubbed a “functional cure,” has been achieved with a simian vaccine aimed at inducing a response by the monkeys’ “killer T-cells,” another weapon in the immune system’s arsenal.
Meanwhile, cure-focused studies of elite controllers are yielding clues about regions of the virus that mutate less, which could hold important lessons for vaccine researchers.
At that time, the world secured the donor funding and introduced the innovating finance mechanisms that enabled widespread vaccine distribution and led to better ways to combat HIV, malaria, and other diseases.
Unfortunately, action has been lacking in the development of new diagnostics, vaccines (and vaccine alternatives), and antibiotics.
Gavi, the Vaccine Alliance, is helping to distribute a new vaccine, and if the immunization drive is successful, it will eventually lead to a reduction in unnecessary antibiotic use, which is the main factor fueling the rise and spread of deadly superbugs everywhere.
For example, global coverage for the Hib vaccine is 72%, but only about 44% of the world’s children receive the complete course of the pneumococcal vaccine.
Universal vaccination for the pneumococcal vaccine alone would lead to an estimated annual reduction of 11.4 million days of antibiotics for children under five.
To accomplish that goal – and stave off AMR in the process – significantly more money must be spent on vaccine research and development.
Although more needs to be done to strengthen R&D pipelines for new diagnostic tools and antibiotics to treat drug-resistant infections, similar attention must be devoted to vaccine discovery, development, and uptake.
And there would be money left over to help develop an HIV vaccine, deliver drugs to treat heart attacks, provide a Hepatitis B vaccine to the developing world, and prevent 31 million children from starving each year.
For the sake of argument, assume that the poorest half of the population cannot afford some vaccine that would ensure them basic good health.
The vaccine scenario is just one example of the kind of complications that can arise.
Golden Rice offers the potential to make contributions to human health and welfare as monumental as the discovery and distribution of the Salk polio vaccine.
Moreover, last year Pakistan became the first country in the region to introduce the latest vaccine to protect children against pneumonia.
With pneumonia accounting for a shockingly high 20% of child deaths each year in Pakistan, widespread access to the new vaccine should have a major impact.
Given the risks involved, it is not surprising that pharmaceutical companies are very careful in their choice of investments in new drug or vaccine programs, selecting only those that promise financial gains sufficient to cover the costs of both successes and failures and provide a reasonable return on the required investment.
But, as a result of the Brazilian outbreak, research into Zika has accelerated, and it is reasonable to hope that a vaccine, anti-viral drug, or other means of combating the infection or its spread will be found.
BackNext